4DMedical received CE Mark certification for its CT:VQ™ technology for commercial use in the European Union. The company secured A$83 million in private placement funding to support growth initiatives. The new funding will be used to support commercial expansion in Europe and software development.
Philips has officially received FDA 510(k) clearance for its EchoNavigator R5.0 system, marking a significant milestone for the company's medical technology division. The new solution leverages artificial intelligence (AI) to assist clinicians during complex, minimally invasive heart valve repair procedures. By…
Read the full storyAstraZeneca PLC announced that its drug tozorakimab successfully cleared two Phase III clinical trials for chronic obstructive pulmonary disease (COPD). The drug met its primary goals by significantly reducing exacerbations in patients, particularly those with low eosinophil levels who represent 35% of cases.…
4DMedical Limited (ASX: 4DX) has achieved a major regulatory milestone by receiving the CE Mark certification for its CT:VQ™ imaging software. This authorization allows the company to commence commercial operations across the European Union, marking a pivotal step in its international growth strategy. Alongside this…